JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263207

Human FXYD5 (Dysadherin) knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

FXYD5 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

View Alternative Names

Dysad, Dysadherin, FXYD domain-containing ion transport regulator 5, FXYD5RIC, FXYD5_HUMAN, HSPC 113, IWU 1, KCT 1, Keratinocytes associated transmembrane protein 1, OIT 2, PRO 6241, RIC

1 Images
Sanger Sequencing - Human FXYD5 (Dysadherin) knockout HEK-293T cell lysate (AB263207)
  • Sanger seq

Unknown

Sanger Sequencing - Human FXYD5 (Dysadherin) knockout HEK-293T cell lysate (AB263207)

Homozygous : 1 bp insertion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263207-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human FXYD5 knockout HEK293T cell lysate", "number":"AB263207-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB263207-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
FXYD5
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Dysadherin also known as FXYD domain-containing ion transport regulator 5 (FXYD5) is a small protein with a mass of approximately 20 kDa. It localizes on the cell surface as a glycoprotein. The protein has wide expression across various tissues including epithelial tissues and certain cancerous cells. Dysadherin has been primarily identified in cells involved in malignancy and metastasis which suggests its role in cancer biology.
Biological function summary

Dysadherin contributes to cell-cell adhesion disruption facilitating the metastatic spread of cancer cells. It is not part of a known protein complex but it interacts with the extracellular matrix to alter cellular cohesion and mobility. By influencing the cellular adhesion properties dysadherin may play a part in the invasive characteristics of some epithelial tumors. This alteration can drive processes leading to carcinoma progression by reducing cell-cell interaction stability.

Pathways

Disruptions in cell adhesion mediated by proteins like dysadherin can impact the epithelial-mesenchymal transition (EMT) pathway significantly. Within this pathway dysadherin decreases E-cadherin expression which weakens cellular adhesion enhancing cell motility and invasiveness. Also it may engage in the PI3K/AKT signaling pathway by affecting cellular growth and survival. Dysadherin might act together with other regulatory proteins that modulate cell adhesion and mobility impacting tumor behavior and progression.

Dysadherin's expression links closely with metastatic cancers including colorectal cancer and breast cancer. Its role in reducing E-cadherin function means it connects to diseases where diminished cell adhesion contributes to cancer metastasis. Dysadherin has associations with other proteins implicated in these diseases such as integrins which also influence metastatic cell movement and invasion. Understanding dysadherin's function and interactions may provide insight into therapeutic strategies for tackling metastatic disease.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com